Table 2.
Baseline clinical characteristics of PsA patients according to ACR50/DAPSA75% response at 6 months after treatment.
| Characteristics* | All patients(n=30) | Complete follow up (n=20) | P Value | |
|---|---|---|---|---|
| Responders(n=7) | Non- Responders (n=13) | |||
| Female (%) | 22 (73%) | 5 (71%) | 8 (61%) | |
| Age, years | 51.1 (10) | 49.4 (9.5) | 51.6 (9) | 0.6 |
| Duration of arthritis, years | 6.2 (5.8) | 7.2 (7.8) | 7 (1.2) | 0.9 |
| Duration of psoriasis, years | 20.3 (12.1) | 27 (10) | 19.3 (10.5) | 0.1 |
| Baseline disease activity by DAPSA | 46 (15.3) | 45.7 (17.5) | 46.8 (15.5) | 0.8 |
| ESR (mm/hr) | 23.1 (18.5) | 25.4 (19.6) | 20 (15) | 0.4 |
| Baseline treatment, n | ||||
| Naïve | 11 | 2 | 4 | |
| DMARDs | 5 | 2 | 1 | |
| Biologics | 14 | 3 | 8 | |
*All values are presented as ‘mean (SD)’ unless otherwise stated. All variables had <20% missing data. PsA, Psoriatic Arthritis; DAPSA, Disease Activity Score for Psoriatic Arthritis; ESR, Erythrocyte Sedimentation Rate; DMARDS, Disease Modifying Anti-Rheumatic Drugs.